Trial Profile
Proof of Concept; A Pilot, Randomized, Double-Blind Study of Oseltamivir Versus Placebo for Immune Thrombocytopenia
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs Oseltamivir (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Biomarker; Proof of concept; Therapeutic Use
- 20 Oct 2020 Planned End Date changed from 1 Nov 2019 to 1 Sep 2021.
- 20 Oct 2020 Planned primary completion date changed from 1 Jan 2019 to 1 Sep 2021.
- 10 May 2018 New trial record